Boston Scientific Reports Strong Q4 and Full Year 2025 Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 04 2026
0mins
Source: PRnewswire
- Significant Sales Growth: Boston Scientific achieved net sales of $5.286 billion in Q4 2025, representing a 15.9% increase, with an organic growth rate of 12.7%, indicating strong market demand and competitiveness in the medical technology sector.
- Improved Profitability: The company reported GAAP net income of $672 million in Q4, translating to an EPS of $0.45, a notable increase from $566 million and $0.38 a year ago, reflecting successful cost control and operational efficiency.
- Strong Annual Performance: For the full year 2025, net sales reached $20.074 billion, up 19.9% with an organic growth rate of 15.8%, demonstrating the company's ongoing expansion and innovation capabilities in the global market.
- Optimistic Future Outlook: The company projects net sales growth of 10.5% to 11.5% for 2026, with adjusted EPS expected to be between $3.43 and $3.49, showcasing management's confidence in future performance and market potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 49.110
Low
94.00
Averages
108.14
High
132.00
Current: 49.110
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology and vascular therapies (ICVT), watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Shares Drop 15% Amid Analyst Downgrades
- Product Line Weakness: Boston Scientific acknowledged potential stagnation in sales of its Watchman heart implant line, contributing to a 15% drop in stock price this week, reflecting market concerns about future growth prospects.
- Analyst Downgrades: Wells Fargo analyst Lawrence Biegelsen downgraded Boston Scientific's rating from overweight to equal weight and reduced the price target from $75 to $55, indicating a pessimistic outlook on the company's future performance.
- Revenue Growth Guidance: Despite facing challenges, Boston Scientific maintained its guidance for organic revenue growth of 6.5% to 8% for 2026, demonstrating confidence in long-term growth potential.
- Increased Market Competition: Analysts noted that new drugs under development by pharmaceutical companies could heighten competitive pressure, particularly in other product categories like urology, further impacting the company's market position.
See More
Boston Scientific Shares Plummet Amid Weak Product Forecast
- Product Line Weakness: Boston Scientific CEO Mike Mahoney indicated at Bernstein's Annual Strategic Decisions Conference that sales of the Watchman heart implants may stagnate, with revenue expected to remain flat in both the current and following quarters, reflecting a shift in market demand away from standalone procedures, which could impact overall performance.
- Analyst Downgrades: Amid increasing pessimism, Wells Fargo analyst Lawrence Biegelsen downgraded the stock from overweight to equal weight and reduced the price target from $75 to $55, highlighting concerns over the new Watchman forecast and weakness in other product lines, such as urology.
- Significant Market Reaction: As of early Friday morning, Boston Scientific's shares had dropped by 15%, reflecting investor concerns about the company's future growth potential, particularly in the face of increasing competition that could affect its market share.
- Positive Long-Term Outlook: Despite short-term challenges, Boston Scientific maintained its guidance for organic revenue growth of 6.5% to 8% for 2026, indicating the company's long-term potential in the medical device sector, suggesting that investors may view this week's stock decline as an opportunity to acquire quality shares at a discount in a vibrant industry.
See More
Boston Scientific Faces Pressure Amid Weak Watchman Procedures
- Boston Scientific's Decline: CEO Michael Mahoney indicated that standalone Watchman procedures are weakening, leading to a 12% stock drop on Wednesday, hitting a two-year low of $50.04, which underscores the growth pressures in the medical device market.
- Li Auto's Loss Expectations: Li Auto's stock reached a 52-week low of $15.3 ahead of its earnings report, with analysts forecasting a RMB2.08 ($0.31) per-share loss, highlighting the intensified competition and price declines in China's EV market impacting profitability.
- BJ's Wholesale Earnings Outlook: BJ's Wholesale Club faced selling pressure as investors questioned its near-term earnings, with a 10-basis-point decline in merchandise margins in Q1, prompting DA Davidson to lower its price target to $105 while maintaining a 'Buy' rating, indicating challenges in the retail sector.
- Market Sentiment Shift: Despite Boston Scientific, Li Auto, and BJ's stocks hitting new 52-week lows, retail sentiment shifted from 'bearish' to 'bullish', reflecting investor expectations for potential rebounds in the near future.
See More
Boston Scientific Shares Plunge 12.64% Amid Soft Growth Outlook
- Weak Guidance: Boston Scientific's management reiterated its full-year organic growth guidance, projecting organic sales growth between 5.5% and 7% for 2026 and 6% to 8% for Q2, but analysts believe the lower end may be more realistic due to flat sales growth expectations for the WATCHMAN device.
- Severe Market Reaction: The company's stock closed at $50.42 on Wednesday, down 12.53% from the previous day, with trading volume reaching 49.5 million shares, about 191% above its three-month average, indicating market concerns over the company's outlook.
- Challenges for WATCHMAN: Although the WATCHMAN device remains the market share leader in its niche, its slowdown in growth has diminished investor confidence in future sales, particularly with muted expectations for Q2 and Q3.
- Industry Pressure: Peers like Abbott and Stryker also faced declines of 1.14% and 2.24%, respectively, reflecting broader pressures across the medical device sector, prompting investors to reassess the market environment.
See More
Boston Scientific Shares Drop 12.53% Amid Soft Growth Guidance
- Stock Price Decline: Boston Scientific (BSX) closed at $50.42 on Wednesday, down 12.53%, primarily due to management reiterating soft full-year organic growth guidance and signaling weaker demand in key WATCHMAN and urology franchises.
- Surge in Trading Volume: The company experienced a trading volume of 49.5 million shares, approximately 191% above its three-month average of 17 million shares, indicating strong market reactions to its outlook.
- Adjusted Growth Expectations: While the company projects organic sales growth of 5.5% to 7% for 2026, analysts believe the lower end of this guidance may be more realistic due to expectations of flat sequential sales growth for the WATCHMAN device in Q2 and Q3.
- Competitive Market Pressure: Competitors in the medical device sector, such as Abbott and Stryker, also faced declines, closing at $85.68 (-1.14%) and $305.99 (-2.24%), reflecting broader industry challenges.
See More
Boston Scientific Invests $1.5 Billion in MiRus for TAVR Market Entry
- Market Entry Strategy: Boston Scientific's $1.5 billion investment in MiRus LLC for a 34% stake positions the company in the transcatheter aortic valve replacement (TAVR) market, projected to grow from $4.5 billion in 2024 to $12.2 billion by 2033, demonstrating its commitment to expansion in the medical device sector.
- Acquisition Potential: This investment not only grants Boston Scientific immediate ownership of one-third of MiRus but also lays the groundwork for a potential 100% acquisition, allowing for an additional $3 billion payment if MiRus's TAVR system meets specific milestones, thereby mitigating investment risks.
- Insider Buying Signal: While 92% of analysts rate Boston Scientific as a buy, the recent purchase of over $500,000 in shares by three directors indicates strong insider confidence in the company's future, further bolstering market sentiment towards the stock.
- Buyback Plan and Growth Outlook: Boston Scientific has also announced a $2 billion accelerated buyback program, signaling management's favorable view of the stock's valuation, while analysts project earnings growth of over 16% annually over the next three to five years, making the current stock price appear attractive.
See More
Boston Scientific Shares Drop 15% Amid Analyst Downgrades
- Product Line Weakness: Boston Scientific acknowledged potential stagnation in sales of its Watchman heart implant line, contributing to a 15% drop in stock price this week, reflecting market concerns about future growth prospects.
- Analyst Downgrades: Wells Fargo analyst Lawrence Biegelsen downgraded Boston Scientific's rating from overweight to equal weight and reduced the price target from $75 to $55, indicating a pessimistic outlook on the company's future performance.
- Revenue Growth Guidance: Despite facing challenges, Boston Scientific maintained its guidance for organic revenue growth of 6.5% to 8% for 2026, demonstrating confidence in long-term growth potential.
- Increased Market Competition: Analysts noted that new drugs under development by pharmaceutical companies could heighten competitive pressure, particularly in other product categories like urology, further impacting the company's market position.
See More
Boston Scientific Shares Plummet Amid Weak Product Forecast
- Product Line Weakness: Boston Scientific CEO Mike Mahoney indicated at Bernstein's Annual Strategic Decisions Conference that sales of the Watchman heart implants may stagnate, with revenue expected to remain flat in both the current and following quarters, reflecting a shift in market demand away from standalone procedures, which could impact overall performance.
- Analyst Downgrades: Amid increasing pessimism, Wells Fargo analyst Lawrence Biegelsen downgraded the stock from overweight to equal weight and reduced the price target from $75 to $55, highlighting concerns over the new Watchman forecast and weakness in other product lines, such as urology.
- Significant Market Reaction: As of early Friday morning, Boston Scientific's shares had dropped by 15%, reflecting investor concerns about the company's future growth potential, particularly in the face of increasing competition that could affect its market share.
- Positive Long-Term Outlook: Despite short-term challenges, Boston Scientific maintained its guidance for organic revenue growth of 6.5% to 8% for 2026, indicating the company's long-term potential in the medical device sector, suggesting that investors may view this week's stock decline as an opportunity to acquire quality shares at a discount in a vibrant industry.
See More
Boston Scientific Faces Pressure Amid Weak Watchman Procedures
- Boston Scientific's Decline: CEO Michael Mahoney indicated that standalone Watchman procedures are weakening, leading to a 12% stock drop on Wednesday, hitting a two-year low of $50.04, which underscores the growth pressures in the medical device market.
- Li Auto's Loss Expectations: Li Auto's stock reached a 52-week low of $15.3 ahead of its earnings report, with analysts forecasting a RMB2.08 ($0.31) per-share loss, highlighting the intensified competition and price declines in China's EV market impacting profitability.
- BJ's Wholesale Earnings Outlook: BJ's Wholesale Club faced selling pressure as investors questioned its near-term earnings, with a 10-basis-point decline in merchandise margins in Q1, prompting DA Davidson to lower its price target to $105 while maintaining a 'Buy' rating, indicating challenges in the retail sector.
- Market Sentiment Shift: Despite Boston Scientific, Li Auto, and BJ's stocks hitting new 52-week lows, retail sentiment shifted from 'bearish' to 'bullish', reflecting investor expectations for potential rebounds in the near future.
See More
Boston Scientific Shares Plunge 12.64% Amid Soft Growth Outlook
- Weak Guidance: Boston Scientific's management reiterated its full-year organic growth guidance, projecting organic sales growth between 5.5% and 7% for 2026 and 6% to 8% for Q2, but analysts believe the lower end may be more realistic due to flat sales growth expectations for the WATCHMAN device.
- Severe Market Reaction: The company's stock closed at $50.42 on Wednesday, down 12.53% from the previous day, with trading volume reaching 49.5 million shares, about 191% above its three-month average, indicating market concerns over the company's outlook.
- Challenges for WATCHMAN: Although the WATCHMAN device remains the market share leader in its niche, its slowdown in growth has diminished investor confidence in future sales, particularly with muted expectations for Q2 and Q3.
- Industry Pressure: Peers like Abbott and Stryker also faced declines of 1.14% and 2.24%, respectively, reflecting broader pressures across the medical device sector, prompting investors to reassess the market environment.
See More
Boston Scientific Shares Drop 12.53% Amid Soft Growth Guidance
- Stock Price Decline: Boston Scientific (BSX) closed at $50.42 on Wednesday, down 12.53%, primarily due to management reiterating soft full-year organic growth guidance and signaling weaker demand in key WATCHMAN and urology franchises.
- Surge in Trading Volume: The company experienced a trading volume of 49.5 million shares, approximately 191% above its three-month average of 17 million shares, indicating strong market reactions to its outlook.
- Adjusted Growth Expectations: While the company projects organic sales growth of 5.5% to 7% for 2026, analysts believe the lower end of this guidance may be more realistic due to expectations of flat sequential sales growth for the WATCHMAN device in Q2 and Q3.
- Competitive Market Pressure: Competitors in the medical device sector, such as Abbott and Stryker, also faced declines, closing at $85.68 (-1.14%) and $305.99 (-2.24%), reflecting broader industry challenges.
See More
Boston Scientific Invests $1.5 Billion in MiRus for TAVR Market Entry
- Market Entry Strategy: Boston Scientific's $1.5 billion investment in MiRus LLC for a 34% stake positions the company in the transcatheter aortic valve replacement (TAVR) market, projected to grow from $4.5 billion in 2024 to $12.2 billion by 2033, demonstrating its commitment to expansion in the medical device sector.
- Acquisition Potential: This investment not only grants Boston Scientific immediate ownership of one-third of MiRus but also lays the groundwork for a potential 100% acquisition, allowing for an additional $3 billion payment if MiRus's TAVR system meets specific milestones, thereby mitigating investment risks.
- Insider Buying Signal: While 92% of analysts rate Boston Scientific as a buy, the recent purchase of over $500,000 in shares by three directors indicates strong insider confidence in the company's future, further bolstering market sentiment towards the stock.
- Buyback Plan and Growth Outlook: Boston Scientific has also announced a $2 billion accelerated buyback program, signaling management's favorable view of the stock's valuation, while analysts project earnings growth of over 16% annually over the next three to five years, making the current stock price appear attractive.
See More
